# OnCo record nct06979596 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06979596/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06979596", "NCT06979596" ;
  schema:name "A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)"@en ;
  schema:alternateName "OMAHA-015"@en ;
  schema:description "A phase 2 trial of Opevesostat, Dexamethasone, Fulvestrant, Exemestane, Megestrol acetate and Tamoxifen in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06979596/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06979596> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-08-11" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/opevesostat/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/exemestane/>, <https://onco.cc/drugs/megestrol/>, <https://onco.cc/drugs/tamoxifen/> ;
  onco:companies <https://onco.cc/companies/merck/> .